Plasma cell rich acute rejection: Risk factors, treatment and outcomes
Plasma cell-rich rejection is a rare and poorly defined entity. Its treatment is not clearly defined and has universally poor prognosis. More data should be published from various transplant centers around the world to identify the treatment that has the best outcomes and to formulate treatment guid...
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wolters Kluwer Medknow Publications
2021-01-01
|
| Series: | Saudi Journal of Kidney Diseases and Transplantation |
| Online Access: | http://www.sjkdt.org/article.asp?issn=1319-2442;year=2021;volume=32;issue=2;spage=387;epage=397;aulast=Mendonca |
| _version_ | 1828133827242885120 |
|---|---|
| author | Satish Mendonca Ananth Rao Manu Dogra Vivek Sood S Prakash G Batta A Dua A Joshi U K Sharma R Tiwari |
| author_facet | Satish Mendonca Ananth Rao Manu Dogra Vivek Sood S Prakash G Batta A Dua A Joshi U K Sharma R Tiwari |
| author_sort | Satish Mendonca |
| collection | DOAJ |
| description | Plasma cell-rich rejection is a rare and poorly defined entity. Its treatment is not clearly defined and has universally poor prognosis. More data should be published from various transplant centers around the world to identify the treatment that has the best outcomes and to formulate treatment guidelines for these cases. It is a retrospective analysis of kidney biopsies form 2008 to 2018. Four hundred biopsied were screened and 55 were found to have features of rejection and among them, 13 had plasma cell-rich rejection. Data of treatment given and the graft survival outcomes in these cases were retrieved by medical records. One patient had complete recovery, three had graft loss and the remaining nine had permanent decline in glomerular filtration rate. Decrease in immunosuppression and presence of infection are risk factors for plasma cell-rich acute rejection (PCAR). It can be acute cell-mediated rejection (ACR)/antibody-mediated rejection (AMR)/ACR+AMR. Resistant rejection, ACR+AMR, C4d positivity, and severe interstitial inflammation are poor prognostic factors. Overzealous decrease in immunosuppression should not be done. Management of immunosuppression during infection is most critical for the development of PCAR. Bortezomib is emerging as a therapeutic modality for the treatment of PCAR. |
| first_indexed | 2024-04-11T17:25:12Z |
| format | Article |
| id | doaj.art-fb08a06fcdfb4befa3f3c8ea53d0bf09 |
| institution | Directory Open Access Journal |
| issn | 1319-2442 |
| language | English |
| last_indexed | 2024-04-11T17:25:12Z |
| publishDate | 2021-01-01 |
| publisher | Wolters Kluwer Medknow Publications |
| record_format | Article |
| series | Saudi Journal of Kidney Diseases and Transplantation |
| spelling | doaj.art-fb08a06fcdfb4befa3f3c8ea53d0bf092022-12-22T04:12:23ZengWolters Kluwer Medknow PublicationsSaudi Journal of Kidney Diseases and Transplantation1319-24422021-01-0132238739710.4103/1319-2442.335451Plasma cell rich acute rejection: Risk factors, treatment and outcomesSatish MendoncaAnanth RaoManu DograVivek SoodS PrakashG BattaA DuaA JoshiU K SharmaR TiwariPlasma cell-rich rejection is a rare and poorly defined entity. Its treatment is not clearly defined and has universally poor prognosis. More data should be published from various transplant centers around the world to identify the treatment that has the best outcomes and to formulate treatment guidelines for these cases. It is a retrospective analysis of kidney biopsies form 2008 to 2018. Four hundred biopsied were screened and 55 were found to have features of rejection and among them, 13 had plasma cell-rich rejection. Data of treatment given and the graft survival outcomes in these cases were retrieved by medical records. One patient had complete recovery, three had graft loss and the remaining nine had permanent decline in glomerular filtration rate. Decrease in immunosuppression and presence of infection are risk factors for plasma cell-rich acute rejection (PCAR). It can be acute cell-mediated rejection (ACR)/antibody-mediated rejection (AMR)/ACR+AMR. Resistant rejection, ACR+AMR, C4d positivity, and severe interstitial inflammation are poor prognostic factors. Overzealous decrease in immunosuppression should not be done. Management of immunosuppression during infection is most critical for the development of PCAR. Bortezomib is emerging as a therapeutic modality for the treatment of PCAR.http://www.sjkdt.org/article.asp?issn=1319-2442;year=2021;volume=32;issue=2;spage=387;epage=397;aulast=Mendonca |
| spellingShingle | Satish Mendonca Ananth Rao Manu Dogra Vivek Sood S Prakash G Batta A Dua A Joshi U K Sharma R Tiwari Plasma cell rich acute rejection: Risk factors, treatment and outcomes Saudi Journal of Kidney Diseases and Transplantation |
| title | Plasma cell rich acute rejection: Risk factors, treatment and outcomes |
| title_full | Plasma cell rich acute rejection: Risk factors, treatment and outcomes |
| title_fullStr | Plasma cell rich acute rejection: Risk factors, treatment and outcomes |
| title_full_unstemmed | Plasma cell rich acute rejection: Risk factors, treatment and outcomes |
| title_short | Plasma cell rich acute rejection: Risk factors, treatment and outcomes |
| title_sort | plasma cell rich acute rejection risk factors treatment and outcomes |
| url | http://www.sjkdt.org/article.asp?issn=1319-2442;year=2021;volume=32;issue=2;spage=387;epage=397;aulast=Mendonca |
| work_keys_str_mv | AT satishmendonca plasmacellrichacuterejectionriskfactorstreatmentandoutcomes AT ananthrao plasmacellrichacuterejectionriskfactorstreatmentandoutcomes AT manudogra plasmacellrichacuterejectionriskfactorstreatmentandoutcomes AT viveksood plasmacellrichacuterejectionriskfactorstreatmentandoutcomes AT sprakash plasmacellrichacuterejectionriskfactorstreatmentandoutcomes AT gbatta plasmacellrichacuterejectionriskfactorstreatmentandoutcomes AT adua plasmacellrichacuterejectionriskfactorstreatmentandoutcomes AT ajoshi plasmacellrichacuterejectionriskfactorstreatmentandoutcomes AT uksharma plasmacellrichacuterejectionriskfactorstreatmentandoutcomes AT rtiwari plasmacellrichacuterejectionriskfactorstreatmentandoutcomes |